$LLY

AI 分析

生成於 May 18, 2026

AI Score
77/ 100
Buy$LLY

Eli Lilly and Company

$LLYNYSEHealthcareMega-Cap

Eli Lilly discovers, develops, and markets pharmaceutical products for endocrinology, oncology, and immunology worldwide.

Market Cap
$850B
Revenue (TTM)
$48.5B
+32.8%
Net Income (TTM)
$12.8B
+45.5%
EPS (TTM)
$14.25
P/E Ratio
62.5
Dividend Yield
0.6%
52-Week Range
$680-$980
Beta
0.42
Dimension Scores
Fundamental
80
Technical
72
Sentiment
80
Risk / Reward
74
Momentum
70
FundTechSentRiskMome
Financial Health
Profitability
82strong
Growth
92strong
Liquidity
78moderate
Solvency
70moderate
Efficiency
75moderate

Valuation, technical analysis, investment thesis, risk assessment and more for $LLY

Free · No credit card required

免責聲明: AI 生成的分析僅供教育參考,不構成投資建議。請始終諮詢合格的理財顧問。

探索更多

用 AI 分析任意股票

獲取涵蓋基本面、技術面、情緒面、風險評估和投資論點的結構化研究報告——約 60 秒完成。